2 Information about voxelotor

Marketing authorisation indication


Voxelotor (Oxbryta, Pfizer) is indicated for 'the treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide'.

Dosage in the marketing authorisation



The list price of voxelotor is £5,917.81 for a 90‑pack of 500‑mg tablets (excluding VAT; BNF online accessed April 2024). The company has a commercial arrangement. This makes voxelotor available to the NHS with a discount. The size of the discount is commercial in confidence.